Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient's physiological status; Acumen Hypotension Prediction Index, an advanced algorithm that indicates the likelihood of a patient developing hypotension; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
Phone949-250-2500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.72 billion
Profitability
Miscellaneous
Employees12,800
Next Earnings Date7/25/2019 (Estimated)
OptionableOptionable
Edwards Lifesciences (NYSE:EW) Frequently Asked Questions
What is Edwards Lifesciences' stock symbol?
Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."
When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?
Shares of Edwards Lifesciences split before market open on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly minted shares were payable to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.
How will Edwards Lifesciences' stock buyback program work?
Edwards Lifesciences announced that its board has initiated a stock buyback plan on Thursday, December 7th 2017, which permits the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company's board believes its stock is undervalued.
How were Edwards Lifesciences' earnings last quarter?
Edwards Lifesciences Corp (NYSE:EW) released its quarterly earnings data on Tuesday, April, 23rd. The medical research company reported $1.32 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.23 by $0.09. The medical research company earned $993 million during the quarter, compared to analyst estimates of $989.87 million. Edwards Lifesciences had a net margin of 20.03% and a return on equity of 31.16%. Edwards Lifesciences's revenue was up 11.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.22 EPS. View Edwards Lifesciences' Earnings History.
When is Edwards Lifesciences' next earnings date?
What guidance has Edwards Lifesciences issued on next quarter's earnings?
Edwards Lifesciences issued an update on its second quarter earnings guidance on Tuesday, April, 23rd. The company provided EPS guidance of $1.27-1.37 for the period, compared to the Thomson Reuters consensus estimate of $1.33. The company issued revenue guidance of $1.02-1.08 billion, compared to the consensus revenue estimate of $1.04 billion.Edwards Lifesciences also updated its FY 2019 guidance to $5.10-5.35 EPS.
What price target have analysts set for EW?
21 brokers have issued 1 year target prices for Edwards Lifesciences' shares. Their forecasts range from $120.00 to $221.00. On average, they expect Edwards Lifesciences' stock price to reach $186.40 in the next year. This suggests a possible upside of 8.0% from the stock's current price. View Analyst Price Targets for Edwards Lifesciences.
What is the consensus analysts' recommendation for Edwards Lifesciences?
21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 2 sell ratings, 7 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Edwards Lifesciences.
What are Wall Street analysts saying about Edwards Lifesciences stock?
Here are some recent quotes from research analysts about Edwards Lifesciences stock:
- 1. According to Zacks Investment Research, "Edwards Lifesciences has reported better-than-expected first-quarter 2019 figures. The company has been seeing strong transcatheter valve sales in the domestic and overseas markets. It has registered strong sales within its Critical Care division, boosted by a surge in HemoSphere sales. Currently, Edwards Lifesciences awaits the full-market launch of the HemoSphere platform with FloTrac System and Acumen Hypotension Predictive Index. The company is also upbeat about the acquisition of CASMED, expected to strengthen its position in smart monitoring technologies within the critical care platform. Further, we are pleased with Edwards Lifesciences’ recent receipt of the CE Mark for PASCAL. Overall, in the past three months, Edwards Lifesciences outperformed its industry. Meanwhile, persistent supply constraints dented Cardioband system sales. This apart, tough competition in the cardiac devices market and reimbursement issues raise concerns." (5/16/2019)
- 2. BTIG Research analysts commented, "As we cautioned in our Q1 preview, TAVR results missed Street estimates. While we have no doubt that the underlying market remains strong, results have been light for 4+ quarters now, making us question if the market growth is a tad less than expected or if share is slightly shifting. Even so, management maintained an upbeat tone and there was no change to TAVR guidance but with Boston Scientific’s (BSX, Lotus approved in the U.S. tonight, we have to think that combined with weak Q1 results, shares may see pressure. On longer-term drivers, mitral sales were $4M in Q1 and although early feedback on PASCAL has fostered management’s own confidence in its outlook, we feel hitting $40M in revenue this year is a lofty goal. On the positive side, we would point to management’s bullishness on the revenue ramp in 2H and the solid expense control driving the EPS beat." (4/24/2019)
- 3. Northland Securities analysts commented, "We analyze data on MitraClip + GDMT in HFpEF / HFrEF + FMR, & impact on existing clinical trials in both transcatheter mitral repair / replacement programs. There are a ton of unknowns, however, it is likely that: 1) Edwards PASCAL trial will need to be redesigned with MitraClip as the control (even though the trial is in DMR; Medtronic’ APOLLO trial, especially in HFrEF might" not need MitraClip as the comparator). 2) COAPT results are not applicable in real-world setting. Key Points We confess, we don’t have access to raw data in COAPT, hence it is impossible to make definitive arguments." (10/11/2018)
Has Edwards Lifesciences been receiving favorable news coverage?
News headlines about EW stock have trended somewhat positive on Wednesday, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Edwards Lifesciences earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an impact on the stock's share price in the next few days.
Who are some of Edwards Lifesciences' key competitors?
Some companies that are related to Edwards Lifesciences include Intuitive Surgical (ISRG), Align Technology (ALGN), Zimmer Biomet (ZBH), COLOPLAST A/S/ADR (CLPBY), Smith & Nephew (SNN), Steris (STE), DEMANT A S/ADR (WILYY), MSA Safety (MSA), Wright Medical Group (WMGI), Avanos Medical (AVNS), Inogen (INGN), Wound Management Technologies (WNDM), Establishment Labs (ESTA), RTI Surgical (RTIX) and ConforMIS (CFMS).
What other stocks do shareholders of Edwards Lifesciences own?
Who are Edwards Lifesciences' key executives?
Edwards Lifesciences' management team includes the folowing people:
- Mr. Michael A. Mussallem, Chairman & CEO (Age 66)
- Mr. Scott B. Ullem, Corp. VP & CFO (Age 52)
- Mr. Donald E. Bobo Jr., Corp. VP of Strategy & Corp. Devel. (Age 57)
- Mr. Robert W. A. Sellers, Principal Accounting Officer, VP & Corp. Controller
- Dr. Todd J. Brinton, Corp. VP of Advanced Technology & Chief Scientific Officer
Who are Edwards Lifesciences' major shareholders?
Edwards Lifesciences' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.25%), FMR LLC (3.92%), Wellington Management Group LLP (3.08%), Jennison Associates LLC (2.76%), Geode Capital Management LLC (1.41%) and Janus Henderson Group PLC (1.27%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Institutional Ownership Trends for Edwards Lifesciences.
Which institutional investors are selling Edwards Lifesciences stock?
EW stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Artisan Partners Limited Partnership, Janus Henderson Group PLC, MERIAN GLOBAL INVESTORS UK Ltd, Morgan Stanley, Amundi Pioneer Asset Management Inc., Victory Capital Management Inc. and Neuberger Berman Group LLC. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Insider Buying and Selling for Edwards Lifesciences.
Which institutional investors are buying Edwards Lifesciences stock?
EW stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, BlackRock Inc., FMR LLC, AKO Capital LLP, Charles Schwab Investment Management Inc., American Century Companies Inc., Los Angeles Capital Management & Equity Research Inc. and The Manufacturers Life Insurance Company . View Insider Buying and Selling for Edwards Lifesciences.
How do I buy shares of Edwards Lifesciences?
Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Edwards Lifesciences' stock price today?
One share of EW stock can currently be purchased for approximately $172.66.
How big of a company is Edwards Lifesciences?
Edwards Lifesciences has a market capitalization of $36.00 billion and generates $3.72 billion in revenue each year. The medical research company earns $722.20 million in net income (profit) each year or $4.70 on an earnings per share basis. Edwards Lifesciences employs 12,800 workers across the globe.
What is Edwards Lifesciences' official website?
How can I contact Edwards Lifesciences?
Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]
MarketBeat Community Rating for Edwards Lifesciences (NYSE EW)
MarketBeat's community ratings are surveys of what our community members think about Edwards Lifesciences and other stocks. Vote "Outperform" if you believe EW will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EW will underperform the S&P 500 over the long term. You may vote once every thirty days.
